VivoSeq
Other

Temozolomide

0

Pipeline Programs↗

8

Active Trials↗

8

Companies Involved↗

Temozolomide is an early-stage landscape with 0 programs across 8 companies. The most active players are Merck & Co., Orphelia Pharma, Rigel Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalO

Orphelia Pharma

0 programs

PreclinicalR

Rigel Pharmaceuticals

0 programs

PreclinicalD

DelMar Pharmaceuticals, Inc.

0 programs

PreclinicalIpsen logo

Ipsen

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

34

clinical trials

Completed22 · 65%
Recruiting7 · 21%
Terminated4 · 12%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

34 trials

Study of Olutasidenib and Temozolomide in HGG
Recruiting·RRigel Pharmaceuticals·Phase 2·NCT06161974·60 enrolled
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
Recruiting·National Cancer Institute, Naples·Phase 2·NCT04893785·35 enrolled
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Recruiting·NNationwide Children's Hospital·Phase 2·NCT05843253·120 enrolled
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
Recruiting·UUniversity of Birmingham·Phase 2·NCT05629702·120 enrolled
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Recruiting·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 2·NCT06450041·62 enrolled
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Recruiting·NNationwide Children's Hospital·Phase 1/2·NCT04211675·31 enrolled
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
Recruiting·VVA Office of Research and Development·Phase 1/2·NCT06681220·166 enrolled
Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07457775·24 enrolled
Combination Paclitaxel, Carboplatin and Temozolomide
Completed·NNew Mexico Cancer Research Alliance·Phase 1·NCT00249964·15 enrolled
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Completed·Merck & Co. logoMerck & Co.·N/A·NCT00723827·682 enrolled
TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Completed·OOrphelia Pharma·Phase 1·NCT04610736·49 enrolled
Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
Completed·Merck & Co. logoMerck & Co.·N/A·NCT00705198·1,804 enrolled
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00006358·44 enrolled
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
Completed·IIstituto Oncologico Veneto IRCCS·Phase 1·NCT06095375·21 enrolled
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
Completed·UUniversity of Oklahoma·Phase 1·NCT00222443·40 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)